Introduction / Overview
Asthma constitutes a chronic, heterogeneous inflammatory airway disease characterized by variable airflow limitation and bronchial hyperresponsiveness. The therapeutic paradigm has evolved from symptomatic bronchodilation to targeted modulation of airway inflammation. Inhaled corticosteroids (ICS) and leukotriene antagonists have emerged as pivotal agents in this context. Their roles in both stepwise disease control and exacerbation prevention are emphasized in contemporary guidelines. The interaction between pharmacologic action and clinical outcomes necessitates a thorough understanding of the underlying mechanisms, pharmacokinetic properties, and patient‑specific considerations. This chapter aims to delineate the pharmacology of corticosteroids and leukotriene antagonists within asthma treatment, thereby equipping medical and pharmacy students with essential knowledge for evidence‑based practice.
- Describe the pharmacologic classes of inhaled corticosteroids and leukotriene antagonists used in asthma.
- Explain the molecular mechanisms that underlie anti‑inflammatory effects of corticosteroids and leukotriene pathway modulation.
- Summarize pharmacokinetic attributes influencing dosing regimens and therapeutic monitoring.
- Identify common adverse effects, contraindications, and drug‑drug interactions pertinent to clinical practice.
- Apply pharmacologic principles to special populations, including pregnant, pediatric, geriatric, and patients with hepatic or renal impairment.
Classification
Inhaled Corticosteroids
Inhaled corticosteroids represent a subclass of glucocorticoids engineered for pulmonary delivery. Common agents include beclomethasone dipropionate, budesonide, fluticasone propionate, mometasone furoate, and ciclesonide. These compounds differ in lipophilicity, receptor affinity, and metabolic stability, thereby influencing potency and systemic exposure.
Leukotriene Antagonists
Leukotriene antagonists are divided into two principal categories: cysteinyl leukotriene receptor antagonists and leukotriene synthesis inhibitors. Montelukast and pranlukast target the cysteinyl leukotriene receptor type 1 (CysLT1), whereas zileuton inhibits 5‑lipoxygenase (5‑LO), preventing leukotriene formation. Structural variations affect pharmacodynamics and the ability to cross the blood‑brain barrier.
Mechanism of Action
Inhaled Corticosteroids
Glucocorticoid receptors (GR) are cytosolic proteins that, upon ligand binding, translocate to the nucleus and modulate gene transcription. The anti‑inflammatory effect is primarily mediated through up‑regulation of anti‑inflammatory proteins (e.g., annexin‑1, lipocortin‑1) and down‑regulation of pro‑inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules). Inhaled delivery concentrates the drug in the bronchial mucosa, limiting systemic GR activation and thereby reducing systemic glucocorticoid exposure. Additionally, corticosteroids inhibit phospholipase A₂, curtailing arachidonic acid release and downstream eicosanoid synthesis, which further dampens inflammation.
Leukotriene Antagonists
Montelukast and pranlukast competitively inhibit CysLT1 receptors located on airway smooth muscle, inflammatory cells, and vascular endothelium. This blockade prevents leukotriene‑mediated bronchoconstriction, mucus secretion, and eosinophil recruitment. Zileuton, by inhibiting 5‑LO, blocks the conversion of arachidonic acid to leukotriene A4, thereby reducing the synthesis of all downstream leukotrienes (LTB₄, LTC₄, LTD₄, LTE₄). The cumulative result is a decrease in airway edema, hyperresponsiveness, and inflammatory cell infiltration.
Pharmacokinetics
Inhaled Corticosteroids
Absorption occurs predominantly within the pulmonary epithelium. The fraction that escapes local metabolism is absorbed systemically, with peak plasma concentrations typically reached within 1–2 hours post‑inhalation. Distribution is extensive due to high lipophilicity; plasma protein binding ranges from 98% to 99%. Metabolism proceeds mainly via hepatic cytochrome P450 enzymes (CYP3A4 for fluticasone, CYP2C9 for beclomethasone). Elimination is primarily biliary, with a terminal half‑life of 3–6 hours for most agents. Systemic bioavailability is generally low (<5%) for inhaled formulations, a factor that informs minimal dosing to achieve therapeutic effect while limiting systemic exposure.
Leukotriene Antagonists
Montelukast is absorbed orally with a bioavailability of approximately 70% after a single dose, reaching peak plasma concentrations within 3–4 hours. Its distribution volume is moderate (Vd ≈ 100 L). Metabolism occurs via hepatic CYP2C8, with a half‑life of about 6–7 hours. Zileuton demonstrates lower oral bioavailability (~35%) due to first‑pass metabolism but has a longer half‑life (~12–15 hours) owing to extensive hepatic conjugation pathways. Both agents are primarily excreted in feces; renal excretion is minimal. The pharmacokinetic profiles support once‑daily dosing regimens for both inhaled corticosteroids and oral leukotriene antagonists.
Therapeutic Uses / Clinical Applications
Inhaled Corticosteroids
ICS are the cornerstone of anti‑inflammatory therapy in persistent asthma. They are indicated for the maintenance of control in mild to severe disease, with dosing escalated according to the stepwise approach. Combination with long‑acting β₂‑agonists (LABA) is recommended for patients whose symptoms remain uncontrolled on high‑dose monotherapy. Off‑label applications include management of chronic obstructive pulmonary disease (COPD) exacerbations and aspirin‑induced asthma, although evidence is variable.
Leukotriene Antagonists
Montelukast and pranlukast are indicated as monotherapy or add‑on therapy for mild persistent asthma, particularly in patients with exercise‑induced bronchoconstriction or aspirin‑hypersensitivity. Zileuton is used similarly but is typically reserved for patients who cannot tolerate or do not respond to other leukotriene antagonists. Off‑label uses encompass allergic rhinitis and urticaria, wherein leukotriene modulation can offer symptomatic relief.
Adverse Effects
Inhaled Corticosteroids
Common local adverse events include oral candidiasis, dysphonia, and cough. Systemic effects are generally minimized but may include growth suppression in children, adrenal suppression, osteoporosis, and increased risk of cataracts with prolonged high‑dose use. Rare but serious complications encompass systemic steroid‑induced hyperglycemia, hypertension, and increased susceptibility to infections.
Leukotriene Antagonists
Montelukast is generally well tolerated; reported side effects include headache, abdominal discomfort, and, infrequently, behavioral changes such as agitation or depression. Zileuton carries a black box warning for hepatotoxicity; liver function monitoring is advised during therapy. Rare allergic reactions, including anaphylaxis, have been documented for both drug classes.
Drug Interactions
Inhaled Corticosteroids
Concomitant use of potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can elevate systemic corticosteroid levels, potentially exacerbating adrenal suppression. Proton pump inhibitors may reduce absorption of some inhaled corticosteroids. LABA agents may potentiate the risk of bronchospasm if misused, although the interaction is primarily pharmacodynamic.
Leukotriene Antagonists
Montelukast is a moderate inhibitor of CYP2C8, which could increase plasma concentrations of drugs metabolized by this enzyme (e.g., phenytoin). Zileuton, a potent CYP3A4 inhibitor, may elevate levels of co‑administered statins and other substrates, raising the risk of myopathy or rhabdomyolysis. Careful monitoring of liver enzymes is essential when co‑prescribing hepatotoxic agents.
Special Considerations
Pregnancy / Lactation
Inhaled corticosteroids are classified as category C; evidence suggests that controlled use results in minimal fetal exposure, yet caution is advised. Montelukast and pranlukast are category B, whereas zileuton is category C due to limited data. Breastfeeding considerations indicate that low systemic absorption reduces the likelihood of significant infant exposure, yet monitoring for potential adverse effects is prudent.
Pediatric / Geriatric Considerations
Growth suppression is a primary concern in pediatric patients on high‑dose inhaled corticosteroids; regular growth assessment and dose minimization are recommended. In geriatric populations, comorbidities such as osteoporosis and diabetes necessitate vigilant monitoring for systemic corticosteroid side effects. Dose adjustments may be required for both age groups based on pharmacokinetic variability.
Renal / Hepatic Impairment
ICS are predominantly metabolized hepatically; severe hepatic dysfunction may necessitate dose reduction or selection of agents with lower hepatic metabolism. Montelukast and pranlukast exhibit minimal renal excretion; thus, renal impairment does not typically require dose modification. Zileuton should be avoided in patients with hepatic insufficiency due to its hepatotoxic potential.
Summary / Key Points
- Inhaled corticosteroids serve as the mainstay anti‑inflammatory therapy for persistent asthma, delivering local effects while limiting systemic exposure.
- Leukotriene antagonists target downstream mediators of inflammation, offering an alternative or adjunctive strategy, particularly in exercise‑induced or aspirin‑hypersensitive asthma.
- Pharmacokinetic profiles inform once‑daily dosing and highlight the importance of monitoring for drug‑drug interactions, especially involving CYP enzymes.
- Common adverse effects of corticosteroids are predominantly local; systemic risks increase with high doses and prolonged use.
- Leukotriene antagonists are generally well tolerated; zileuton requires liver function surveillance due to hepatotoxicity risk.
- Special populations demand tailored dosing strategies and vigilant monitoring: pregnant women, children, the elderly, and patients with hepatic or renal impairment.
- Effective asthma management relies on aligning pharmacologic mechanisms with individual patient profiles, thereby optimizing therapeutic outcomes while minimizing adverse events.
References
- Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
- Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
- Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
- Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
- Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
- Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
- Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
- Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
⚠️ Medical Disclaimer
This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.
The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.